Hims & Hers Health (NYSE:HIMS) Shares Up 3.2%

Hims & Hers Health, Inc. (NYSE:HIMS) shot up 3.2% during mid-day trading on Tuesday . The company traded as high as $23.47 and last traded at $22.85. 2,784,346 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 7,168,997 shares. The stock had previously closed at $22.15.

Wall Street Analysts Forecast Growth

Several research firms have commented on HIMS. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. Seaport Res Ptn restated a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Canaccord Genuity Group initiated coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective on the stock. Jefferies Financial Group reiterated a “hold” rating and set a $15.00 target price (down from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Finally, Bank of America boosted their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.43.

Hims & Hers Health Trading Down 6.9 %

The stock has a market capitalization of $4.63 billion, a PE ratio of -2,156.00 and a beta of 1.08. The business’s 50 day moving average is $17.27 and its 200 day moving average is $13.36.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The firm had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. The company’s quarterly revenue was up 45.8% on a year-over-year basis. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.19 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Oluyemi Okupe sold 11,546 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $22.21, for a total transaction of $256,436.66. Following the completion of the sale, the chief financial officer now directly owns 177,449 shares of the company’s stock, valued at $3,941,142.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Oluyemi Okupe sold 11,546 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $22.21, for a total transaction of $256,436.66. Following the completion of the sale, the chief financial officer now owns 177,449 shares of the company’s stock, valued at $3,941,142.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,503 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $15.65, for a total value of $39,171.95. Following the completion of the sale, the insider now owns 166,866 shares of the company’s stock, valued at approximately $2,611,452.90. The disclosure for this sale can be found here. Insiders have sold a total of 962,791 shares of company stock worth $16,930,725 over the last quarter. Company insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new stake in Hims & Hers Health in the fourth quarter worth about $48,000. Avantax Advisory Services Inc. bought a new stake in shares of Hims & Hers Health in the 1st quarter valued at about $156,000. Cornerstone Investment Partners LLC purchased a new stake in shares of Hims & Hers Health in the 1st quarter worth approximately $161,000. Belpointe Asset Management LLC bought a new position in shares of Hims & Hers Health during the third quarter valued at approximately $76,000. Finally, Certuity LLC purchased a new position in Hims & Hers Health during the fourth quarter valued at approximately $109,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.